Clinical Trial Update: A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids [Phase 3]

View source ↗

Summary

A Phase 3 placebo-controlled trial evaluating relugolix (TAK-385) 40 mg for pain symptoms due to uterine fibroids has completed; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Fibroids

Drugs mentioned

• Relugolix (Relugolix)

Snippet

Sponsor: Takeda | Conditions: Uterine Fibroids | Phase 3 | Status: COMPLETED | Results posted: 2019-03-22